Prudential Financial’s Karyopharm Therapeutics KPTI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$211K Buy
+172,610
New +$706K ﹤0.01% 2297
2025
Q1
– Sell
-4,973
Closed -$50.5K – 2340
2024
Q4
$50.5K Hold
4,973
– – ﹤0.01% 2209
2024
Q3
$61.9K Buy
+4,973
New +$61.8K ﹤0.01% 2622
2024
Q2
– Sell
-1,308
Closed -$29.6K – 2749
2024
Q1
$29.6K Sell
1,308
-346
-21% -$6.07K ﹤0.01% 2633
2023
Q4
$21.5K Buy
1,654
+360
+28% +$4.85K ﹤0.01% 2612
2023
Q3
$26K Buy
+1,294
New +$29K ﹤0.01% 2558
2023
Q1
– Sell
-920
Closed -$46.9K – 2634
2022
Q4
$46.9K Sell
920
-1,193
-56% -$82.7K ﹤0.01% 2495
2022
Q3
$173K Sell
2,113
-1,320
-38% -$98.6K ﹤0.01% 2470
2022
Q2
$232K Buy
+3,433
New +$315K ﹤0.01% 2423
2019
Q2
– Sell
-5,902
Closed -$517K – 2472
2019
Q1
$517K Buy
5,902
+1,000
+20% +$111K ﹤0.01% 2077
2018
Q4
$689K Buy
4,902
+3,434
+234% +$579K ﹤0.01% 1924
2018
Q3
$375K Sell
1,468
-32
-2% -$8.85K ﹤0.01% 2122
2018
Q2
$382K Sell
1,500
-3,082
-67% -$762K ﹤0.01% 2115
2018
Q1
$923K Buy
4,582
+3,307
+259% +$659K ﹤0.01% 1874
2017
Q4
$184K Buy
+1,275
New +$205K ﹤0.01% 2270

Other funds holding KPTI

Prudential Financial's KPTI Position: Q3 2026 in Review

Prudential Financial opened a new position in Karyopharm Therapeutics (KPTI) in Q3 2026: 172,610 shares worth $211K. The stake represents ﹤0.01% of the portfolio and ranks #2297 among its holdings. This is a return to the name: Prudential Financial previously reported a position in KPTI as recently as Q4 2024.

Prudential Financial first reported a position in KPTI in Q4 2017 and has held it in 15 quarters since. The position peaked at $923K in Q1 2018. 92 funds tracked by Wall St. Rank hold KPTI as of Q3 2026.

  • Prudential Financial held 172,610 shares of Karyopharm Therapeutics worth $211K as of Q3 2026.
  • Karyopharm Therapeutics was a new Prudential Financial position in Q3 2026.
  • Karyopharm Therapeutics made up ﹤0.01% of Prudential Financial's portfolio in Q3 2026, its #2297 holding.
  • Prudential Financial first reported a position in Karyopharm Therapeutics in Q4 2017 and has held it in 15 quarters since.
  • Prudential Financial's Karyopharm Therapeutics position peaked at $923K in Q1 2018.
  • 92 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q3 2026.

Based on Prudential Financial's 13F filing for Q3 2026, filed 16 Nov 2026.